In 2015, BioForward launched the tradition of recognizing, on an annual basis, scientific and business achievements in the biosciences. As we look to the future, we reflect back on the successes that have brought Wisconsin to be among the leaders in biomedical research and development. Our recipients in 2015, captured Wisconsin’s broad impact on global human health, and additionally, their scientific and business contributions have had a significant impact on Wisconsin’s economy.
Hector is former chairman of the University’s Biochemistry Department. He is well known for his discovery of the vitamin D-basedendocrine system and the development of 8 pharmaceuticals used worldwide.
He was elected to the United States National Academy of Sciences in 1979. Hector has trained almost 160 graduate students and has more than 700 patents to his name. In addition, DeLuca is president and CEO of Deltanoid Pharmaceuticals, a biotechnology company founded on technology he developed, and has been responsible for the development of Bone Care, Int. (acquired by Genzyme) and Tetrionics (now Sigma Aldrich Fine Chemicals acquired by Merck).
Hector has received many national and international awards, including the Gairdner Award of Canada, the Roussel Prize of France, the 3M Life Sciences Award of the Federation of American Societies for Experimental Biology, the Rank Award from London and he holds three honorary doctorate degrees.
Bill Linton founded Promega in 1978 and has served continuously as Chairman, President and Chief Executive Officer. A life science research company, Promega has grown from one employee to a global corporation, employing over 1,300 people worldwide. Today, Promega serves customers in over 100 countries, with direct sales and manufacturing branches in 16 countries. Initially supporting university researchers, Promega now serves scientists in basic research, drug discovery, forensics and clinical diagnostics. The company continues to be privately held with revenues of $380 million.
Collaboration and partnering continue to be cornerstones of the Promega model. In the late 1980s, Promega established, through joint venture, several of the earliest biotechnology companies in the People’s Republic of China. Promega continues to promote and support partnering in order to best serve customers and ultimately facilitate scientific discovery.
That same philosophy extends to community support, both local and global. In 1991, Promega established Woods Hollow Children’s Center (WHCC), providing infant through school-age childcare for the local community as well as Promega employees. In 1993, The BioPharmaceutical Technology Center Institute (BTC Institute), a non-profit educational, scientific and cultural institute, was established. Promega has long been a financial supporter of various arts and education pursuits as well. As an employer, Promega is recognized for creating an “employee as individual” workplace, acknowledging and supporting work-life balance and nurturing personal and professional creativity and innovation.
Bill has served on a number of industry, government and community boards. He is currently a member of the board of directors of the Analytical, Life Science and Diagnostics Association (ALDA), Bruker Biosciences, BioPharmaceutical Technology Center Institute, and Heffter Research Institute. Bill received a Bachelor of Science degree in Biological Sciences from the University of California, Berkeley. He conducted post-graduate work in Pharmaceutical Chemistry at the University of Wisconsin-Madison and received honorary doctorates from Hannam University, Daejon, South Korea, and the University of Wisconsin-Madison.